Candel Therapeutics Inc Dossier - Source-backed chat

Candel Therapeutics Inc

CADLNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.02

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.16Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $777.4M

Enterprise Value $577.6M

Shares Outstanding 67.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Candel Therapeutics is transitioning from a clinical-stage R&D biotech to a pre-commercial company, backed by robust Phase 3 data for its lead candidate aglatimagene besadenovec (CAN-2409) in localized prostate cancer. With a significantly bolstered balance sheet following a $100 million equity offering and a $100 million royalty funding agreement, the company has extended its cash runway into Q1 2028. This runway fully covers the critical regulatory milestone of a planned BLA submission in Q4 2026 and prepares the company for a potential commercial launch in 2027. Additionally, its pipeline-in-a-product strategy is validated by ongoing Phase 3 development in non-small cell lung cancer (NSCLC) and promising Phase 1b data for CAN-3110 in recurrent high-grade glioma.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$20.50

High · most bullish analyst$29.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0020%

CMC process validation issues delay the planned Q4 2026 BLA submission for CAN-2409, or the FDA requests additional clinical data, pushing back the commercial timeline. Delayed timelines increase the cash burn rate, leading to potential equity dilution before commercialization.

Base CaseCentral scenario

$18.6750%

Candel successfully completes process validation and submits the BLA for CAN-2409 in localized prostate cancer in Q4 2026. The Phase 3 NSCLC trial begins enrollment, and the cash runway remains sufficient into Q1 2028, supporting launch readiness activities for a 2027 commercial entry.

Bull CaseUpside scenario

$26.0030%

The FDA approves CAN-2409 in localized prostate cancer without requiring an advisory committee delay, triggering the $100 million royalty funding agreement with RTW Investments. Simultaneously, the pivotal Phase 3 trial in NSCLC initiates smoothly and shows early positive signals, while CAN-3110 demonstrates exceptional survival benefits in glioma, attracting a major pharmaceutical partnership.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pivotal Phase 3 data for CAN-2409 in localized prostate cancer demonstrated a significant 30% improvement in disease-free survival.
Strong cash position of $194.8 million as of March 31, 2026, providing an operational runway into Q1 2028.
Strategic $100 million royalty funding agreement with RTW Investments secures non-dilutive capital contingent on FDA approval.
Fast Track and RMAT designations from the FDA for CAN-2409 accelerate the regulatory pathway.

Key Investment Risks

Regulatory risks associated with the upcoming BLA submission, including potential CMC or manufacturing validation delays.
Clinical development risks in expanding CAN-2409 into advanced NSCLC and pancreatic cancer.
Dependence on third-party contract manufacturers (CDMOs) for scale-up and commercial supply.

Thesis Invalidation Triggers

Failure to achieve successful process validation with the CDMO in 2026, delaying the BLA submission.
FDA refusal to file or complete the review of the CAN-2409 BLA.
Severe safety signals emerging from the ongoing CAN-3110 or CAN-2409 clinical trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.